Cardiology in Review最新文献_第3页

Ultra-Early Blood Pressure Control in Acute Intracerebral Hemorrhage. 急性脑出血的超早期血压控制。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-03-24 DOI: 10.1097/CRD.0000000000000904

Janelle O Poyant, Brianne M Ritchie

{"title":"Ultra-Early Blood Pressure Control in Acute Intracerebral Hemorrhage.","authors":"Janelle O Poyant, Brianne M Ritchie","doi":"10.1097/CRD.0000000000000904","DOIUrl":"10.1097/CRD.0000000000000904","url":null,"abstract":"Acute intracerebral hemorrhage (ICH) remains one of the most devastating neurological emergencies, with blood pressure (BP) management in the early hours playing a pivotal role in determining patient outcomes. Emerging evidence suggests that ultra-early BP control-intervening within minutes to 2 hours of symptom onset-has the potential to reduce secondary brain injury and improve survival. Yet, despite this evidence, current clinical practice is often inconsistent, and there is no universally agreed-upon approach for managing BP in the acute phase of ICH. We advocate for ultra-early BP intervention as a standard of care in ICH, as it offers a clear opportunity to mitigate damage and to enhance recovery. We contend that current BP management protocols are often too conservative and fail to recognize the critical importance of acting swiftly. The first few hours represent a unique window in which targeted interventions, such as continuous infusion intravenous antihypertensives, may limit hematoma expansion and stabilize cerebral perfusion pressure. However, achieving optimal outcomes requires more than just aggressive treatment-it demands a tailored approach to BP control, accounting for individual patient factors, evolving clinical conditions, and operational aspects of care. We advocate for a paradigm shift toward prioritizing ultra-early intervention, supported by clear, evidence-based protocols and real-time decision-making.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"287-290"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Paradigm Shift in Hydrocephalus Management: The Promise of Endovascular Cerebrospinal Fluid Diversion. 脑积水治疗的范式转变：血管内脑脊液转移的前景。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-03-26 DOI: 10.1097/CRD.0000000000000886

Abdelaziz Amllay, Charles C Matouk

{"title":"A Paradigm Shift in Hydrocephalus Management: The Promise of Endovascular Cerebrospinal Fluid Diversion.","authors":"Abdelaziz Amllay, Charles C Matouk","doi":"10.1097/CRD.0000000000000886","DOIUrl":"10.1097/CRD.0000000000000886","url":null,"abstract":"Normal pressure hydrocephalus (NPH) predominantly affects the elderly and is the most common form of adult-onset hydrocephalus. Clinically, it is characterized by Hakim's triad-gait disturbance, dementia, and urinary incontinence-and is marked by abnormal cerebrospinal fluid accumulation without increased intracranial pressure. Although the exact pathophysiology is not fully understood, proposed mechanisms include glymphatic dysfunction, blood-brain barrier disruption, and hypoperfusion. In carefully selected patients, the standard treatment, ventriculoperitoneal shunting, can provide significant improvement in gait stability and urinary incontinence, and to a lesser extent, cognitive decline. However, ventriculoperitoneal shunting carries substantial risks, including infection, need for revision, and over-drainage, highlighting the urgent need for safer, more effective treatment options. CereVasc's eShunt System is a promising, minimally invasive alternative. This 3-cm biomimetic device is deployed via a percutaneous transvenous approach in the inferior petrosal sinus. It is deployed across the wall of the venous sinus and dura mater and thereby mimics the function of an arachnoid granulation by passively diverting cerebrospinal fluid from the cerebellopontine angle cistern into the internal jugular vein. It is hoped that this minimally invasive approach will reduce the risks associated with conventional shunting. This brief opinion piece reviews NPH, the challenges of current treatments, and the potential of the eShunt System. Preliminary data from ongoing clinical trials suggest that the eShunt System may represent a minimally invasive treatment option for patients with NPH and other forms of communicating hydrocephalus. Furthermore, this technology may serve as a platform for advanced central nervous system drug delivery, broadening its impact on neurointerventional therapies.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"294-297"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Manifestations of Hemochromatosis: A Review of Pathophysiology, Mechanisms, and Treatment Options. 血色素沉着症的心血管表现：病理生理学、机制和治疗方案综述。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-10-26 DOI: 10.1097/CRD.0000000000000622

Shamim Ahmed, Stephen J Peterson, Manish A Parikh, William H Frishman

引用次数: 0

Innovation in the Management of Delayed Cerebral Ischemia in Subarachnoid Hemorrhage. 蛛网膜下腔出血迟发性脑缺血治疗的创新。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-04-17 DOI: 10.1097/CRD.0000000000000921

Pankajavalli Ramakrishnan, Ankita Jain, Eris Spirollari, Ariel Sacknovitz, Fawaz Al-Mufti

{"title":"Innovation in the Management of Delayed Cerebral Ischemia in Subarachnoid Hemorrhage.","authors":"Pankajavalli Ramakrishnan, Ankita Jain, Eris Spirollari, Ariel Sacknovitz, Fawaz Al-Mufti","doi":"10.1097/CRD.0000000000000921","DOIUrl":"10.1097/CRD.0000000000000921","url":null,"abstract":"Aneurysmal subarachnoid hemorrhage is one of the feared stroke subtypes with a high degree of morbidity and mortality. Even after the initial treatment of the ruptured aneurysm, patients remain critically ill due to numerous neurologic and systemic sequalae. Among them is cerebral vasospasm, which is a key contributor in the development of delayed cerebral ischemia (DCI). Whereas prevention of DCI with oral nimodipine is standard of care, neurointerventional strategies in the management of DCI are varied. Chemical angioplasty with intra-arterial vasodilators has been a conventional approach when noninvasive medical management fails but is associated with the need for retreatment and therefore felt to be least durable. Balloon angioplasty is also another classically employed, but less frequent intervention, and is limited by utility in the proximal arterial segment, a narrower safety profile, and challenging navigability. More recently, the use of retrievable stents is emerging as a novel strategy with the advantages of improved safety profile, and navigability to treat more distal segments. Here, a selective overview of some of these classic and innovative neurointerventional strategies is presented in the treatment of symptomatic vasospasm/DCI.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"298-301"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factor XI/XIa Inhibitors: A New Approach to Anticoagulation.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-12-01 DOI: 10.1097/CRD.0000000000000624

Harris Z Whiteson, William H Frishman

{"title":"Factor XI/XIa Inhibitors: A New Approach to Anticoagulation.","authors":"Harris Z Whiteson, William H Frishman","doi":"10.1097/CRD.0000000000000624","DOIUrl":"10.1097/CRD.0000000000000624","url":null,"abstract":"For more than 60 years, anticoagulation drugs have served as a mainstay in preserving and improving the cardiovascular health of patients across the globe. Functioning to reduce a patient's ability to produce blood clots, prescription rates for anticoagulants have been steadily rising year-over-year both in the United States and abroad. Despite decades of clinical usage, modern-day anticoagulants have been shown to predispose an individual to pathological bleeding. Even in seemingly benign instances of bleeding, patients on anticoagulation therapy might require intensive and expensive medical procedures or monitoring. Understanding the clinical implications of pathological bleeding, research and development of future anticoagulants seeking to minimize these effects. One emerging category of anticoagulant drugs are Factor XI/XIa (FXI) inhibitors. Targeting the coagulation cascade, clinical trials of Factor XIa inhibitors have shown promising results in preventing blood clot formation without increasing the instances of spontaneous and/or pathological bleeding events. While still in phase II and III clinical trials, and potentially years away from being implemented as standard of care, these novel drugs might have the potential to improve the safety and quality of life of patients taking anticoagulants. In this review, we discuss a brief history of anticoagulation therapy, followed by an analysis of the potential risks, benefits, and implications of Factor XI/XIa inhibitors across elements of patient care.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"306-311"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proceedings of the New York Symposium: Innovation in Neurosciences: Editors' Introduction. 纽约研讨会论文集：神经科学的创新：编辑介绍。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1097/CRD.0000000000000929

Fawaz Al-Mufti, Stephan A Mayer, Chirag D Gandhi

引用次数: 0

Pitavastatin in the Prevention of Cardiovascular Disease in People Living with HIV: A Review. 匹伐他汀在预防艾滋病病毒感染者心血管疾病中的作用：综述。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2024-01-31 DOI: 10.1097/CRD.0000000000000646

Harris Z Whiteson, Maddison Drogy, Grant Eickel, William H Frishman

{"title":"Pitavastatin in the Prevention of Cardiovascular Disease in People Living with HIV: A Review.","authors":"Harris Z Whiteson, Maddison Drogy, Grant Eickel, William H Frishman","doi":"10.1097/CRD.0000000000000646","DOIUrl":"10.1097/CRD.0000000000000646","url":null,"abstract":"HIV is associated with a wide array of pathophysiologic mechanisms that ultimately contribute to mortality. While HIV is traditionally known as a disease that attacks the immune system, it is now established that infection with HIV can cause cardiovascular disease (CVD). Through inflammation, atherogenesis, interactions with antiretroviral therapy/highly-active antiretroviral therapy (ART/HAART), and other mechanisms, HIV is an independent risk factor for the development of CVD. The treatment of the CVD risks associated with HIV is complicated, especially due to interactions with hyperlipidemic drugs and ART/HAART. There is a prompt need for a drug (or drug class) that is known to reduce the risk of CVD, specifically in people living with HIV. Recently, the randomized trial to prevent vascular events in HIV trial evaluated the usage of pitavastatin in preventing major cardiac events in people with HIV, showing a significant reduction in cardiac events among those taking the therapeutic. In this review, we evaluate the mechanisms by which HIV contributes to CVD, and the randomized trial to prevent vascular events in HIV trial, and postulate about future directions of the drug in treating people living with HIV.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"374-378"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary Artery Stenosis in Tetralogy of Fallot. 法洛四联症肺动脉狭窄。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-11-15 DOI: 10.1097/CRD.0000000000000627

Botao Gao

引用次数: 0

Cor Triatriatum: A Review.

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-11-15 DOI: 10.1097/CRD.0000000000000626

Katherine Kilkenny, William Frishman

引用次数: 0

Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy. Aficasten——一种治疗肥厚型心肌病的二级心肌肌球蛋白抑制剂。

IF 2 4区医学

Cardiology in Review Pub Date : 2025-07-01 Epub Date: 2023-10-25 DOI: 10.1097/CRD.0000000000000620

Jay Patel, Andy Wang, Srihari S Naidu, William H Frishman, Wilbert S Aronow

{"title":"Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy.","authors":"Jay Patel, Andy Wang, Srihari S Naidu, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000620","DOIUrl":"10.1097/CRD.0000000000000620","url":null,"abstract":"Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in a significant majority. The medical management of obstructive hypertrophic cardiomyopathy has evolved over the decades as our understanding has grown. Traditionally, the mainstay in management has included the use of various negative inotropic agents. In contrast, the cardiac myosin inhibitors, aficamten and mavacamten, are novel therapies targeting cardiac contractility at the sarcomere level that have demonstrated improvement in clinical outcomes for patients, and mavacamten (Bristol Myers Squibb, Inc.) has now been approved by the Food and Drug Administration for the treatment of symptomatic obstructive HCM. Aficamten (Cytokinetics, Inc.) is the second in class cardiac myosin inhibitor that is currently being evaluated in ongoing phase III clinical trials, and is the subject of this review.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"365-368"},"PeriodicalIF":2.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50160789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0